Top 10 Companies in the Global API Mannitol Market (2026): Market Leaders Powering Global Pharmaceutical Supply

MARKET INSIGHTS

The Global API Mannitol market was valued at USD 285.6 million in 2024. The market is projected to grow from USD 305.7 million in 2025 to USD 489.2 million by 2032, exhibiting a CAGR of 6.8% during the forecast period.

Mannitol, a sugar alcohol derived from glucose, serves as an active pharmaceutical ingredient (API) with diverse applications across industries. It functions as an osmotic diuretic in pharmaceutical formulations, an excipient in tablet manufacturing, and a sweetening agent in food products. Its superior properties like low hygroscopicity and stability make it ideal for specialized medical applications including renal diagnostics and intravenous therapies.

Market growth is driven by rising demand for pharmaceutical excipients, expansion in renal care treatments, and increasing adoption in food processing. The diabetic‑friendly nature of mannitol as a sugar substitute further propels demand. Recent strategic developments include Roquette’s 2023 expansion of its French production facility to meet growing European demand, highlighting industry efforts to scale capacity in response to market needs.

Global API Mannitol Market – View in Detailed Research Report

Top 10 Companies in the Global API Mannitol Market

1. Roquette Frères (France)
   Key Offering: Pharmaceutical‑grade mannitol via catalytic hydrogenation. Roquette continues to expand its French plant, positioning itself to meet the rising demand for high‑purity excipients in Europe and beyond. The company’s investment in advanced process controls ensures consistent product quality and compliance with stringent pharmacopeial standards.
   • Continued expansion of production capacity in France.
   • Investment in energy‑efficient hydrogenation units.
   • Strategic partnerships with European generic manufacturers.
2. Cargill, Incorporated (USA)
   Key Offering: Dual‑segment production of food‑grade and pharmaceutical‑grade mannitol. Cargill’s global footprint enables it to serve both the food industry and the pharmaceutical supply chain, leveraging its extensive logistics network to reduce lead times.
   • Integration of digital supply‑chain solutions.
   • Focus on sustainable sourcing of raw materials.
   • Collaboration with U.S. and European regulatory bodies.
3. SPI Pharma (Sigachi Industries) (USA/India)
   Key Offering: High‑purity excipient‑grade mannitol with a strong presence in North America and Europe. SPI Pharma’s manufacturing strategy emphasizes stringent GMP compliance and rapid scale‑up capabilities.
   • Expansion of Indian manufacturing sites.
   • Implementation of real‑time quality monitoring.
   • Partnerships with emerging generic manufacturers.
4. Huaxu Pharmaceutical Co., Ltd. (China)
   Key Offering: Bulk API‑grade mannitol produced through catalytic hydrogenation. Huaxu’s production volumes have surged in response to China’s growing domestic pharmaceutical market and export demand.
   • Investment in high‑pressure reactors.
   • Adoption of automated purification lines.
   • Compliance with USP, EP, and JP standards.
5. Lianmeng Chemical Group Co., Ltd. (China)
   Key Offering: Pharmaceutical‑grade mannitol with a focus on cost‑competitiveness. Lianmeng’s strategy aligns with China’s push for self‑sufficiency in critical excipients.
   • Expansion of plant capacity in Jiangsu.
   • Implementation of lean manufacturing practices.
   • Collaboration with domestic generic manufacturers.
6. Bright Moon Seaweed Group Co., Ltd. (China)
   Key Offering: Natural extraction of mannitol from Laminaria species. Bright Moon’s niche position caters to clean‑label and sustainability‑oriented customers in both food and pharmaceutical markets.
   • Development of seaweed cultivation partnerships.
   • Optimization of extraction yields.
   • Certification for organic and clean‑label claims.
7. Ingredion Incorporated (USA)
   Key Offering: Specialty carbohydrates portfolio that includes food‑grade mannitol. Ingredion’s focus on innovation supports the growing demand for low‑calorie sweeteners.
   • Research into novel sweetener blends.
   • Expansion of North American production facilities.
   • Commitment to carbon‑neutral manufacturing.
8. EMD Millipore (Merck KGaA) (Germany)
   Key Offering: High‑purity mannitol for laboratory and pharmaceutical formulation use. EMD Millipore’s distribution network complements its research‑grade product portfolio.
   • Partnerships with global pharmaceutical R&D labs.
   • Investment in analytical instrumentation.
   • Focus on traceability and batch transparency.
9. Merck KGaA (Germany)
   Key Offering: Pharmaceutical‑grade mannitol for injectable and lyophilized products. Merck’s integrated research and manufacturing capabilities enable rapid product development cycles.
   • Investment in cryoprotectant research.
   • Collaboration with biologics developers.
   • Adherence to GMP and EMA guidelines.
10. GSK (GlaxoSmithKline) (UK)
    Key Offering: In‑house production of excipient‑grade mannitol for its global pharmaceutical portfolio. GSK’s vertical integration supports supply chain resilience.
    • Expansion of UK manufacturing capacity.
    • Focus on sustainability in raw material sourcing.
    • Alignment with global quality standards.

Download FREE Sample Report

Get Full Report Here

Outlook to 2034

Extending the forecast to 2034, the Global API Mannitol market is expected to reach approximately USD 650 million, driven by continued adoption of advanced drug delivery systems and the expansion of generic drug manufacturing in emerging economies. The shift toward low‑sugar food products and the rising prevalence of chronic renal conditions will sustain demand for both pharmaceutical and food‑grade mannitol.

Future Trends

1. Digitalization of Supply Chains – Real‑time inventory tracking and predictive analytics will reduce lead times and enhance supplier resilience.
2. Sustainability in Production – Companies are investing in renewable energy sources and waste‑to‑energy solutions to lower the carbon footprint of catalytic hydrogenation.
3. Expansion of Pulmonary Delivery Applications – Inhaled mannitol formulations for cystic fibrosis and bronchiectasis are gaining traction, opening a high‑value niche.
4. Blood‑Brain Barrier Modulation – Early‑stage research into mannitol’s ability to transiently open the BBB is creating new opportunities for CNS drug delivery.